Cargando…

A Novel Glycolysis and Hypoxia Combined Gene Signature Predicts the Prognosis and Affects Immune Infiltration of Patients with Colon Cancer

PURPOSE: We aimed to characterize the expression patterns of glycolysis and hypoxia genes in colon cancers as well as their value in prognosis and immune microenvironment. METHODS: The expression profiles were acquired from the Cancer Genome Atlas database. Enrichment of hypoxia and glycolysis gene...

Descripción completa

Detalles Bibliográficos
Autores principales: Mao, Guochao, Wu, Jianhua, Cui, Hanxiao, Dai, Luyao, Ma, Li, Zhou, Zhangjian, Liang, Baobao, Zhang, Shuqun, Lin, Shuai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847155/
https://www.ncbi.nlm.nih.gov/pubmed/35185344
http://dx.doi.org/10.2147/IJGM.S351831
_version_ 1784651990099296256
author Mao, Guochao
Wu, Jianhua
Cui, Hanxiao
Dai, Luyao
Ma, Li
Zhou, Zhangjian
Liang, Baobao
Zhang, Shuqun
Lin, Shuai
author_facet Mao, Guochao
Wu, Jianhua
Cui, Hanxiao
Dai, Luyao
Ma, Li
Zhou, Zhangjian
Liang, Baobao
Zhang, Shuqun
Lin, Shuai
author_sort Mao, Guochao
collection PubMed
description PURPOSE: We aimed to characterize the expression patterns of glycolysis and hypoxia genes in colon cancers as well as their value in prognosis and immune microenvironment. METHODS: The expression profiles were acquired from the Cancer Genome Atlas database. Enrichment of hypoxia and glycolysis gene sets in colon cancer was identified by gene set enrichment analysis. Then, a prognostic signature was built up after Cox regression analyses, and overall survival analysis validated the predictive ability. Immune status and infiltration in cancer tissues were explored using the single sample gene set enrichment analysis and CIBERSORT algorithm. A nomogram model integrating clinical variables and the gene signature was established and assessed. RESULTS: Altogether, 378 cancer and 39 control cases were enrolled. Three glycolysis gene sets and two hypoxia gene sets were enriched in colon cancer (P < 0.05). Five independent genes (ENO3, GPC1, P4HA1, SPAG4, and STC2) were significantly correlated with prognosis of colon cancer patients. Patients with higher risks had significantly better prognosis than those with lower risks (P = 0.002 and AUC = 0.750), which was also observed in the elderly, female and stage I–II subgroups (P < 0.05). In high-risk cases, proportion of NK cells resting increased (P < 0.05) while that of dendritic cells activated (P < 0.05), dendritic cells resting (P < 0.01) and monocytes (P < 0.01) decreased. Besides, expressions of 22 checkpoint genes were found abnormal in groups with different risks (P < 0.05). The predictive nomogram presented satisfactory performance with C-index of 0.771 (0.712–0.830). The area under ROC curve was 0.796 and 0.803 for 3- and 5-year survival prediction, respectively. CONCLUSION: A glycolysis and hypoxia combined gene signature was a promising method to evaluate the prognosis and immune infiltration of colon cancer patients, which may provide a new tool for cancer management.
format Online
Article
Text
id pubmed-8847155
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-88471552022-02-18 A Novel Glycolysis and Hypoxia Combined Gene Signature Predicts the Prognosis and Affects Immune Infiltration of Patients with Colon Cancer Mao, Guochao Wu, Jianhua Cui, Hanxiao Dai, Luyao Ma, Li Zhou, Zhangjian Liang, Baobao Zhang, Shuqun Lin, Shuai Int J Gen Med Original Research PURPOSE: We aimed to characterize the expression patterns of glycolysis and hypoxia genes in colon cancers as well as their value in prognosis and immune microenvironment. METHODS: The expression profiles were acquired from the Cancer Genome Atlas database. Enrichment of hypoxia and glycolysis gene sets in colon cancer was identified by gene set enrichment analysis. Then, a prognostic signature was built up after Cox regression analyses, and overall survival analysis validated the predictive ability. Immune status and infiltration in cancer tissues were explored using the single sample gene set enrichment analysis and CIBERSORT algorithm. A nomogram model integrating clinical variables and the gene signature was established and assessed. RESULTS: Altogether, 378 cancer and 39 control cases were enrolled. Three glycolysis gene sets and two hypoxia gene sets were enriched in colon cancer (P < 0.05). Five independent genes (ENO3, GPC1, P4HA1, SPAG4, and STC2) were significantly correlated with prognosis of colon cancer patients. Patients with higher risks had significantly better prognosis than those with lower risks (P = 0.002 and AUC = 0.750), which was also observed in the elderly, female and stage I–II subgroups (P < 0.05). In high-risk cases, proportion of NK cells resting increased (P < 0.05) while that of dendritic cells activated (P < 0.05), dendritic cells resting (P < 0.01) and monocytes (P < 0.01) decreased. Besides, expressions of 22 checkpoint genes were found abnormal in groups with different risks (P < 0.05). The predictive nomogram presented satisfactory performance with C-index of 0.771 (0.712–0.830). The area under ROC curve was 0.796 and 0.803 for 3- and 5-year survival prediction, respectively. CONCLUSION: A glycolysis and hypoxia combined gene signature was a promising method to evaluate the prognosis and immune infiltration of colon cancer patients, which may provide a new tool for cancer management. Dove 2022-02-11 /pmc/articles/PMC8847155/ /pubmed/35185344 http://dx.doi.org/10.2147/IJGM.S351831 Text en © 2022 Mao et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Mao, Guochao
Wu, Jianhua
Cui, Hanxiao
Dai, Luyao
Ma, Li
Zhou, Zhangjian
Liang, Baobao
Zhang, Shuqun
Lin, Shuai
A Novel Glycolysis and Hypoxia Combined Gene Signature Predicts the Prognosis and Affects Immune Infiltration of Patients with Colon Cancer
title A Novel Glycolysis and Hypoxia Combined Gene Signature Predicts the Prognosis and Affects Immune Infiltration of Patients with Colon Cancer
title_full A Novel Glycolysis and Hypoxia Combined Gene Signature Predicts the Prognosis and Affects Immune Infiltration of Patients with Colon Cancer
title_fullStr A Novel Glycolysis and Hypoxia Combined Gene Signature Predicts the Prognosis and Affects Immune Infiltration of Patients with Colon Cancer
title_full_unstemmed A Novel Glycolysis and Hypoxia Combined Gene Signature Predicts the Prognosis and Affects Immune Infiltration of Patients with Colon Cancer
title_short A Novel Glycolysis and Hypoxia Combined Gene Signature Predicts the Prognosis and Affects Immune Infiltration of Patients with Colon Cancer
title_sort novel glycolysis and hypoxia combined gene signature predicts the prognosis and affects immune infiltration of patients with colon cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847155/
https://www.ncbi.nlm.nih.gov/pubmed/35185344
http://dx.doi.org/10.2147/IJGM.S351831
work_keys_str_mv AT maoguochao anovelglycolysisandhypoxiacombinedgenesignaturepredictstheprognosisandaffectsimmuneinfiltrationofpatientswithcoloncancer
AT wujianhua anovelglycolysisandhypoxiacombinedgenesignaturepredictstheprognosisandaffectsimmuneinfiltrationofpatientswithcoloncancer
AT cuihanxiao anovelglycolysisandhypoxiacombinedgenesignaturepredictstheprognosisandaffectsimmuneinfiltrationofpatientswithcoloncancer
AT dailuyao anovelglycolysisandhypoxiacombinedgenesignaturepredictstheprognosisandaffectsimmuneinfiltrationofpatientswithcoloncancer
AT mali anovelglycolysisandhypoxiacombinedgenesignaturepredictstheprognosisandaffectsimmuneinfiltrationofpatientswithcoloncancer
AT zhouzhangjian anovelglycolysisandhypoxiacombinedgenesignaturepredictstheprognosisandaffectsimmuneinfiltrationofpatientswithcoloncancer
AT liangbaobao anovelglycolysisandhypoxiacombinedgenesignaturepredictstheprognosisandaffectsimmuneinfiltrationofpatientswithcoloncancer
AT zhangshuqun anovelglycolysisandhypoxiacombinedgenesignaturepredictstheprognosisandaffectsimmuneinfiltrationofpatientswithcoloncancer
AT linshuai anovelglycolysisandhypoxiacombinedgenesignaturepredictstheprognosisandaffectsimmuneinfiltrationofpatientswithcoloncancer
AT maoguochao novelglycolysisandhypoxiacombinedgenesignaturepredictstheprognosisandaffectsimmuneinfiltrationofpatientswithcoloncancer
AT wujianhua novelglycolysisandhypoxiacombinedgenesignaturepredictstheprognosisandaffectsimmuneinfiltrationofpatientswithcoloncancer
AT cuihanxiao novelglycolysisandhypoxiacombinedgenesignaturepredictstheprognosisandaffectsimmuneinfiltrationofpatientswithcoloncancer
AT dailuyao novelglycolysisandhypoxiacombinedgenesignaturepredictstheprognosisandaffectsimmuneinfiltrationofpatientswithcoloncancer
AT mali novelglycolysisandhypoxiacombinedgenesignaturepredictstheprognosisandaffectsimmuneinfiltrationofpatientswithcoloncancer
AT zhouzhangjian novelglycolysisandhypoxiacombinedgenesignaturepredictstheprognosisandaffectsimmuneinfiltrationofpatientswithcoloncancer
AT liangbaobao novelglycolysisandhypoxiacombinedgenesignaturepredictstheprognosisandaffectsimmuneinfiltrationofpatientswithcoloncancer
AT zhangshuqun novelglycolysisandhypoxiacombinedgenesignaturepredictstheprognosisandaffectsimmuneinfiltrationofpatientswithcoloncancer
AT linshuai novelglycolysisandhypoxiacombinedgenesignaturepredictstheprognosisandaffectsimmuneinfiltrationofpatientswithcoloncancer